Exosomal lncRNA NEAT1 induces paclitaxel resistance in breast cancer cells and promotes cell migration by targeting miR-133b

Wei, Xinyu; Tao, Shuang; Mao, Huilan; Zhu, Haitao; Mao, Lingyu; Pei, Wenhao; Shi, Xiuru; Shi, Yingxiang; Zhang, Shiwen; Wu, Yulun; Wei, Ke; Wang, Jing; Pang, Siyan; Wang, Wenrui; Chen, Changjie; Yang, Qingling

doi:10.1016/j.gene.2023.147230

Cited by 14 publications

(5 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The exosomal NEAT1 derived from BC cells induces resistance to paclitaxel in recipient cells. Inhibition of NEAT1 expression with small hairpin RNA (shRNAs) improves paclitaxel response in BC patients [ 116 ]. These studies emphasize that non-coding RNAs can enhance chemosensitivity by modulating gluconeogenesis, whereas less research exists on the role of modulating lipid or amino acid metabolism.…”

Section: Clinical Implications Of Metabolism-regulating Ncrnas In Bre...mentioning

confidence: 99%

Metabolism-regulating non-coding RNAs in breast cancer: roles, mechanisms and clinical applications

Xu,

Wang,

Zhao

et al. 2024

J Biomed Sci

View full text Add to dashboard Cite

Breast cancer is one of the most common malignancies that pose a serious threat to women's health. Reprogramming of energy metabolism is a major feature of the malignant transformation of breast cancer. Compared to normal cells, tumor cells reprogram metabolic processes more efficiently, converting nutrient supplies into glucose, amino acid and lipid required for malignant proliferation and progression. Non-coding RNAs(ncRNAs) are a class of functional RNA molecules that are not translated into proteins but regulate the expression of target genes. NcRNAs have been demonstrated to be involved in various aspects of energy metabolism, including glycolysis, glutaminolysis, and fatty acid synthesis. This review focuses on the metabolic regulatory mechanisms and clinical applications of metabolism-regulating ncRNAs involved in breast cancer. We summarize the vital roles played by metabolism-regulating ncRNAs for endocrine therapy, targeted therapy, chemotherapy, immunotherapy, and radiotherapy resistance in breast cancer, as well as their potential as therapeutic targets and biomarkers. Difficulties and perspectives of current targeted metabolism and non-coding RNA therapeutic strategies are discussed.

show abstract

Section: Clinical Implications Of Metabolism-regulating Ncrnas In Bre...mentioning

confidence: 99%

Metabolism-regulating non-coding RNAs in breast cancer: roles, mechanisms and clinical applications

Xu,

Wang,

Zhao

et al. 2024

J Biomed Sci

View full text Add to dashboard Cite

show abstract

“…Dong et al (2022) found that NEAT1 promotes apoptosis and autophagy in Parkinson's disease (PD) and inhibits the reproduction of dopaminergic neurons by targeting miR-107-5p (see Figure 4C). Wei et al (2023) demonstrated that lncRNA NEAT1 can induce paclitaxel resistance in the breast cancer tumor microenvironment (see Figure 4C). Liu et al (2022) revealed that Metformin plays a therapeutic role in endometrial hyperplasia by regulating the lncRNA MEG3/miR-233/ GLUT4 signaling pathway (see Figure 4D).…”

Section: Discussionmentioning

confidence: 90%

Predict lncRNA-drug associations based on graph neural network

Xu,

Li,

Yuan

et al. 2024

Front. Genet.

View full text Add to dashboard Cite

LncRNAs are an essential type of non-coding RNAs, which have been reported to be involved in various human pathological conditions. Increasing evidence suggests that drugs can regulate lncRNAs expression, which makes it possible to develop lncRNAs as therapeutic targets. Thus, developing in-silico methods to predict lncRNA-drug associations (LDAs) is a critical step for developing lncRNA-based therapies. In this study, we predict LDAs by using graph convolutional networks (GCN) and graph attention networks (GAT) based on lncRNA and drug similarity networks. Results show that our proposed method achieves good performance (average AUCs > 0.92) on five datasets. In addition, case studies and KEGG functional enrichment analysis further prove that the model can effectively identify novel LDAs. On the whole, this study provides a deep learning-based framework for predicting novel LDAs, which will accelerate the lncRNA-targeted drug development process.

show abstract

“…When these MRE-containing lncRNAs or circRNAs competitively bind to miRNAs, it leads to an increase in the level of miRNA-regulated mRNA transcription [71]. The exosome-derived lncRNA NEAT1 upregulated CXCL12 expression through competitively binding to miR-133b, promoted breast cancer cell migration and growth, and induced paclitaxel resistance in breast cancer cells [79]. In their study, Hu et al demonstrated that the transfer of circ_UBE2D2 via exosomes enhances tamoxifen resistance in estrogen receptor-positive breast cancer.…”

Section: Rna-rna Interactionsmentioning

confidence: 99%

Drug resistance in breast cancer is based on the mechanism of exocrine non-coding RNA

Ye,

Chen,

Yang

et al. 2024

Discov Onc

View full text Add to dashboard Cite

Breast cancer (BC) ranks first among female malignant tumors and involves hormonal changes and genetic as well as environmental risk factors. In recent years, with the improvement of medical treatment, a variety of therapeutic approaches for breast cancer have emerged and have strengthened to accommodate molecular diversity. However, the primary way to improve the effective treatment of breast cancer patients is to overcome treatment resistance. Recent studies have provided insights into the mechanisms of resistance to exosome effects in BC. Exosomes are membrane-bound vesicles secreted by both healthy and malignant cells that facilitate intercellular communication. Specifically, exosomes released by tumor cells transport their contents to recipient cells, altering their properties and promoting oncogenic components, ultimately resulting in drug resistance. As important coordinators, non-coding RNAs (ncRNAs) are involved in this process and are aberrantly expressed in various human cancers. Exosome-derived ncRNAs, including microRNAs (miRNAs), long-noncoding RNAs (lncRNAs), and circular RNAs (circRNAs), have emerged as crucial components in understanding drug resistance in breast cancer. This review provides insights into the mechanism of exosome-derived ncRNAs in breast cancer drug resistance, thereby suggesting new strategies for the treatment of BC.

show abstract

Exosomal lncRNA NEAT1 induces paclitaxel resistance in breast cancer cells and promotes cell migration by targeting miR-133b

Cited by 14 publications

References 31 publications

Metabolism-regulating non-coding RNAs in breast cancer: roles, mechanisms and clinical applications

Metabolism-regulating non-coding RNAs in breast cancer: roles, mechanisms and clinical applications

Predict lncRNA-drug associations based on graph neural network

Drug resistance in breast cancer is based on the mechanism of exocrine non-coding RNA

Contact Info

Product

Resources

About